[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-pelvic-pain-syndrome-cpps\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-pelvic-pain-syndrome-cpps":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,48,74,98,126,159],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100095145","genetic-study-of-chronic-prostatitischronic-pelvic-pain-syndrome-cpcpps-100095145",false,"NCT00499317","Genetic Study of Chronic Prostatitis\u002FChronic Pelvic Pain Syndrome (CP\u002FCPPS)","CP\u002FCPPS","Inclusion Criteria:\n\n* Have symptoms for at least 3 months within the preceding 6 months:\n* Pain in the pelvic area\n* Urinary frequency and\u002For\n* Urinary urgency and\u002For\n* Sexual dysfunction (erectile dysfunction)\n* Have CP\u002FCPPS, Interstitial Cystitis (IC), Bladder Pain Syndrome BPS, or Bladder Fasciculation Syndrome (BFS)\n* Be willing to provide a blood\u002Fsaliva, bladder tissue (from previous biopsy) and urine sample\n* Agree to complete several brief questionnaires\n* Family member of someone with CP\u002FCPPS, BPS, IC or BFS\n* Live in the USA or Canada\n\nExclusion Criteria:\n\n* Major structural\u002Fanatomical urinary tract abnormalities\n* Underlying inborn or congenital conditions which affect the urinary tract\n* Surgery\u002Fchemotherapy in the pelvic area\n* Bacterial cause to CP\u002FCPPS or recurrent Urinary tract infections (UTI)\n* Traumatic cause to CP\u002FCPPS","ALL",{"count":18,"type":19},500,"ESTIMATED","OBSERVATIONAL","Chronic Prostatitis\u002FChronic Pelvic Pain Syndrome (CP\u002FCPPS) is a condition with several causes of which some remain unknown. It is believed that some types of CP may be genetic or passed down (inherited) from one generation to the next.\n\nIn this study, we are collecting genetic material and medical information to try to determine if genetic factors play a role in CP\u002FCPPS. We will be collecting DNA (from Blood\u002FSaliva sample) and urine from each participant. Bladder tissue from affected individuals will also be collected. Individuals and families with CP\u002FCPPS will be enrolled. Family members of an individual with CP\u002FCPPS are eligible whether or not they also experience CP\u002FCPPS symptoms.",[23,24,25,26,27],"Chronic Prostatitis (CP)","Chronic Pelvic Pain Syndrome (CPPS)","Painful Bladder Syndrome (PBS)","Benign Frequency Syndrome (BFS)","Interstitial Cystitis",[29,30,31,32,33,34],"Urgency","Frequency","Pelvic pain","Sexual dysfunction","Erectile dysfunction","Painful intercourse","RECRUITING","2026-06-10",{"date":38,"type":39},"2026-06-11","ACTUAL",{"date":41,"type":39},"2007-01-15",{"date":43,"type":19},"2028-12-31",{"name":45,"class":46},"Boston Children's Hospital","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":47},"100637276","oxiblumecoq10-ralivia-therapy-for-chronic-prostatitischronic-pelvic-pain-syndrome-cpcpps-100637276","NCT07629505","Oxiblume:CoQ10 (Ralivia) Therapy for Chronic Prostatitis\u002FChronic Pelvic Pain Syndrome (CP\u002FCPPS)","Oxiblume:CoQ10 (Ralivia) Therapy for Chronic Prostatitis\u002FChronic Pelvic Pain Syndrome (CP\u002FCPPS): a Double-blind Placebo-controlled Randomized Clinical Trial Assessing Treatment Efficacy and Safety.","Inclusion Criteria:\n\n1. Participant must be between 18 and 50 years old.\n2. Participant has signed and dated the appropriate Informed Consent document.\n3. Participant has had a clinical diagnosis of CP\u002FCPPS defined as symptoms of discomfort or pain in the perineal or pelvic region for at least a three (3) month period within the last six (6) months.\n\nExclusion Criteria:\n\n1. Participant has evidence of facultative Gram negative or enterococcus with a value of ≥ 1000 CFU\u002Fml in mid-stream urine (VB2).\n2. Participant has a history of prostate, bladder or urethral cancer.\n3. Participant has undergone pelvic radiation or systemic chemotherapy.\n4. Participant has undergone intravesical chemotherapy.\n5. Participant has unilateral orchialgia without pelvic symptoms, active urethral stricture or bladder stones, or any other urological condition associated with LUTS, any neurological disease or disorder affecting the bladder.\n6. Participant has undergone prostate surgery or treatment.\n7. Participant with penile or urinary sphincter implants.\n8. Participant has been diagnosed with cancer during the last 5 years or had any surgery in the pelvis.\n9. Participant has a neurological impairment or psychiatric disorder preventing his understanding of consent and his ability to comply with the protocol.","MALE","18 Years","50 Years",{"count":59,"type":19},100,"INTERVENTIONAL",[62],"NA","Chronic Prostatitis\u002FChronic Pelvic Pain Syndrome (CP\u002FCPPS) has a huge socioeconomic impact.Presently, a ''scientific dead-end'' regarding effective treatment of CP\u002FCPPS is reported. Promising results of clinical studies, regardless their limitations, upon efficacy of phytotherapy for CP\u002FCPPS patients have been published .Phytotherapy is cost effective and avoids the systemic side effects of other treatments being a therapy with the possibility of repeating the treatment protocol at any time. Certain important issues, regarding the efficacy and safety of phytotherapy, remain to be answered thus investing scientifically and economically to the concept of phytotherapy for CP\u002FCPPS, definitively seems to be a move to the right direction.\n\nIn this concept we will conduct a double-blind placebo-controlled randomized clinical trial assessing treatment efficacy and safety of Oxiblume:CoQ10 (Ralivia) therapy for CP\u002FCPPS\n\nThe study will be coordinated by the research office of 1st Urology Department, G. Gennimatas Hospital, Aristotle University of Thessaloniki, Greece. The research office will also support the project (logistics, quality control, management, data acquisition, publications).\n\nPatients visits will be carried out in the CP\u002FCPPS Research Unit of the 1st Urology Department, G. Gennimatas Hospital, Aristotle University of Thessaloniki, Greece.\n\nLaboratory tests of all patients will be performed at the same microbiology laboratory.\n\nStudy population A total of 100 patients (50 in Group A and 50 in Group B) with CP\u002FCPPS diagnosis will participate in this study.\n\nInclusion and exclusion criteria\n\nInclusion criteria:\n\n1. Participant must be between 18 and 50 years old.\n2. Participant has signed and dated the appropriate Informed Consent document.\n3. Participant has had a clinical diagnosis of CP\u002FCPPS defined as symptoms of discomfort or pain in the perineal or pelvic region for at least a three (3) month period within the last six (6) months.\n\nExclusion criteria:\n\n1. Participant has evidence of facultative Gram negative or enterococcus with a value of ≥ 1000 CFU\u002Fml in mid-stream urine (VB2).\n2. Participant has a history of prostate, bladder or urethral cancer.\n3. Participant has undergone pelvic radiation or systemic chemotherapy.\n4. Participant has undergone intravesical chemotherapy.\n5. Participant has unilateral orchialgia without pelvic symptoms, active urethral stricture or bladder stones, or any other urological condition associated with LUTS, any neurological disease or disorder affecting the bladder.\n6. Participant has undergone prostate surgery or treatment.\n7. Participant with penile or urinary sphincter implants.\n8. Participant has been diagnosed with cancer during the last 5 years or had any surgery in the pelvis.\n9. Participant has a neurological impairment or psychiatric disorder preventing his understanding of consent and his ability to comply with the protocol.\n\nStudy design Double-blind placebo-controlled randomized clinical trial\n\nZero hypothesis (H0) and alternative hypothesis (H1):\n\n(H0): Group A demonstrates similar efficacy compared to Group B for the treatment CP\u002FCPPS patients.\n\n(H1): Group A demonstrates greater or decreased efficacy compared to Group B for the treatment CP\u002FCPPS patients.\n\nStudy endpoints Primary endpoint: The difference between the Group A and Group B in the change of the pain domain of NIH-CPSI score from baseline to 12 weeks after treatment initiation.\n\nSecondary endpoints:\n\n* Adverse events rate in all patients during study period.\n* The difference between the Group A and Group B in the change of the pain domain of NIH-CPSI score from baseline to 6 weeks after treatment start.\n* The difference between the Group A and Group B in the change of the following parameters from baseline to 6 and 12 weeks after treatment initiation\n\n  1. Total NIH-CPSI score (Q1-9)\n  2. Urinary symptoms (Q 5-6) and quality of life domains (Q 7-9) of the NIH-CPSI score\n  3. IIEF-ED score\n  4. IPSS\n  5. UPPOINTS phenotype- number of positive domains\n  6. Psa value\n  7. TNFa, IL 6 values\n\nPatients accordingly to which group they will be randomized will receive:\n\n* Active treatment (Ralivia) Group : 1 pill of Ralivia per os\u002Fday for a 3-month period\n* Placebo Group : 1 placebo pill per os\u002Fday for a 3-month period\n\nAdverse events will be reported.\n\nFU Visit 1: 6 weeks after treatment initiation NIH-CPSI, IPSS, IIEF-ED questionnaires will be answered. Adverse events will be reported. Clinical symptoms assessed, in order to determine UPOINT status.\n\nPSA TNFa, IL 1β, IL 6, IL 10 blood test.\n\nFU Visit 2: 12 weeks after treatment initiation NIH-CPSI, IPSS, IIEF-ED questionnaires will be answered. Adverse events will be reported. Clinical symptoms assessed, in order to determine UPOINT status.\n\nDRE will be performed . PSA TNFa, IL 6 blood test",[24],"2026-06-01",{"date":67,"type":39},"2026-06-05",{"date":69,"type":19},"2026-06-08",{"date":71,"type":19},"2026-12",{"name":73,"class":46},"G.Gennimatas General Hospital",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":81,"minAge":56,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":60,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":47},"100575883","national-program-to-overcome-pelvic-pain-study-poppy-100575883","NCT06778070","National Program to Overcome Pelvic Pain studY (POPPY)","POPPY","Inclusion Criteria:\n\n* Women (individuals reporting female sex assigned at birth who self-identify as women or non-binary) aged 18 years or older\n* Report chronic or recurrent pain in the pelvis (between or below the anterior iliac crests) for at least 6 months\n* Report at least moderate pain intensity based on a screening pain log\n* Report prior clinical evaluation of their pelvic pain by a healthcare professional including at least a superficial pelvic exam\n* Willing to refrain from initiating new clinical treatments that may affect their pain during the study period\n\nExclusion Criteria:\n\n* Report pelvic pain occurring exclusively with menses or exclusively during sexual intercourse (although candidates with at least some pain between menses or intercourse are still eligible)\n* Participation in organized yoga classes or muscle strengthening programs (e.g., Pilates) in the past 4 weeks, or any prior yoga therapy specifically directed at pelvic pain\n* Lacking technical requirements to complete intervention classes by video, including no access to broadband internet or a Zoom-compatible device larger than a smartphone \\[display screen at least 7 inches in diagonal\\] (although the study team may loan devices to participants from underrepresented backgrounds)\n* Currently pregnant (by self-report or screening test), pregnant within the past 12 weeks, or planning pregnancy during the study period\n* Diagnosed with an alternate, reversible cause of pelvic pain that is unlikely to respond to yoga and requires another treatment modality (e.g., current pelvic infection or a gynecologic dermatosis)\n* Surgery or irradiation to the genital or pelvic structures within the past 12 weeks, or anticipating upcoming surgery or irradiation to these structures during the study period\n* Initiation, dose escalation, or weaning of pharmacologic agents that may affect pelvic pain severity in the past 4 weeks, such as analgesics, antidepressants, or anticonvulsants-(however, women on stable doses of these medications for at least 4 weeks will still be eligible)\n* Use of formal psychological therapies specifically for pelvic pain (e.g., systematic desensitization, cognitive therapy, relaxation therapy) within 4 weeks of screening, or plans to engage in these therapies during the study period\n* Unable to walk up a flight of stairs or at least 2 blocks on level ground (i.e., functional capacity \\\u003C 4 METs), or unable to get up from a supine to a standing position without assistance\n* Participation in another interventional study that might interfere with or confound study procedures, or known conflict with multiple upcoming study intervention class dates\n* Inability to understand the informed consent form or fill out questionnaires or complete study interviews\n* Any other serious physical or mental issue that, in the opinion of the investigators, would interfere with study participation (e.g., advanced dementia, uncontrolled substance use or serious mental illness, life expectancy \\\u003C6 months)","FEMALE",{"count":83,"type":19},220,[62],"A randomized, parallel-group, investigator-blinded, comparative effectiveness trial of a fully remote, videoconference-based pelvic floor yoga program versus a physical conditioning program for women with chronic pelvic pain syndrome.",[24,87,88],"Chronic Pelvic Pain Syndrome","Chronic Pelvic Pain","2026-03-04",{"date":91,"type":39},"2026-03-06",{"date":93,"type":39},"2025-05-12",{"date":95,"type":19},"2029-03-15",{"name":97,"class":46},"University of California, San Francisco",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":55,"minAge":56,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":60,"phases":109,"briefSummary":110,"conditions":111,"keywords":112,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":47},"100620401","jing-si-herbal-tea-as-adjuvant-treatment-in-patients-with-chronic-pelvic-pain-syndrome-100620401","NCT07357142","Jing Si Herbal Tea as Adjuvant Treatment in Patients With Chronic Pelvic Pain Syndrome","JING SI HERBAL TEA Use as Adjuvant Treatment in Patients With Chronic Pelvic Pain Syndrome","JSHT-CPPS","Inclusion Criteria:\n\n1. Male patients.\n2. Diagnosed with Chronic Pelvic Pain Syndrome (CPPS) at the investigational site.\n3. Currently receiving continuous follow-up and medical treatment.\n\nExclusion Criteria:\n\n1. Female patients (Excluded because the standard treatment, alpha-blockers, is not approved or reimbursed by the National Health Insurance for this indication in women in Taiwan).\n2. Duration of symptoms less than 3 months.\n3. History of recurrent urinary tract infections.\n4. Diagnosed with malignancy.\n5. Hospitalization for other diseases within the past 3 months.\n6. Unwilling to participate in the study.","100 Years",{"count":108,"type":19},400,[62],"The purpose of this clinical trial is to evaluate the efficacy of Jing Si Herbal Tea as an adjuvant treatment for patients diagnosed with Chronic Pelvic Pain Syndrome (CPPS). The study aims to determine whether adding Jing Si Herbal Tea to standard care can improve clinical symptoms and quality of life in these patients.",[24],[87,113,114,115],"CPPS","Jing Si Herbal Tea","Herbal Medicine","NOT_YET_RECRUITING","2026-02-02",{"date":119,"type":39},"2026-02-04",{"date":121,"type":19},"2026-03-01",{"date":123,"type":19},"2030-12-31",{"name":125,"class":46},"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":81,"minAge":56,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":136,"conditions":137,"keywords":142,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":155,"leadSponsor":157,"locationsCount":47},"100578807","gene-and-molecular-pathways-of-ozone-treatment-response-in-gynecological-tumor-patients-with-chronic-pelvic-pain-secondary-to-cancer-treatment-100578807","NCT06816095","Gene and Molecular Pathways of Ozone Treatment Response in Gynecological Tumor Patients With Chronic Pelvic Pain Secondary to Cancer Treatment","Gene and Molecular Pathway Characterization of the Response to Ozone Treatment in Gynecological Tumor Patients With Chronic Pelvic Pain Secondary to Radio-chemotherapy","OzoGynEpigen","Inclusion Criteria:\n\n* Adult women (\\>=18 years old) with gynecological tumors treated with radiotherapy-chemotherapy.\n* Cancer disease is stable or in remission.\n* Life expectancy \\> = 6 months.\n* Patients included in the group of patients with pelvic pain must have a clinical, radiological, endoscopic, or histopathological diagnosis that their pain is not secondary to the oncological process.\n* Patients included in the group of patients with pelvic pain must have pain for \\>= 3 months duration, with an intensity \\>= 3 on the Visual Analog Scale (VAS), or classified as toxicity \\>= Grade-2 of the CTCAE v.5.0 of the National Cancer Institute of the USA.\n* Signed and dated informed consent specific to this study.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years old.\n* Severe psychiatric disorders.\n* Inability to complete the quality of life questionnaires.\n* Active neoplasia requiring recent initiation (\\\u003C 3 months) of systemic or local treatment.\n* Life expectancy (for any reason) \\\u003C 6 months.\n* Failure to meet all inclusion criteria",{"count":135,"type":19},40,"Gynecological cancers, including those affecting the ovaries, uterus, and cervix, represent a significant health burden for women. While survival rates have improved, many women experience chronic pelvic pain secondary to cancer treatment, especially radiotherapy and chemotherapy. This treatment-induced pelvic pain can be of difficult management and significantly affects patients' quality of life.\n\nIn our experience, ozone therapy has emerged as a promising complementary treatment for pain relief in patients with chronic diseases, including side effects of cancer treatment. However, the genetic and epigenetic mechanisms influencing its effectiveness have not yet been thoroughly studied.\n\nThe aim of this prospective study is to analyze how ozone therapy modulates the expression of certain genes and its impact on epigenetic clocks, which could help predict pain response.",[24,138,139,140,141],"Radiation-Induced Disorder","Radiotherapy Side Effects","Side Effect of Chemotherapy","Gynecological Cancers",[138,139,143,24,141,144,145,146,147,148,149,150],"Cancer survivors","gene expression","epigenetic clocks","side effects of cancer treatment","Toxicity of chemotherapy","Ozone therapy","Quality of Life","oxidative stress","2025-02-10",{"date":153,"type":39},"2025-02-12",{"date":151,"type":39},{"date":156,"type":19},"2027-08-14",{"name":158,"class":46},"Bernardino Clavo, MD, PhD",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":81,"minAge":56,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":60,"phases":169,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":183},"100567816","phase-2-vaginal-photobiomodulation-for-chronic-pelvic-pain-100567816","NCT06673108","Vaginal Photobiomodulation for Chronic Pelvic Pain","Vaginal Photobiomodulation for Chronic Pelvic Pain: a Randomized Controlled Trial","VOICE","Inclusion Criteria:\n\n1. Age 18 years or older;\n2. CPP for 3 months or longer;\n3. Overall pelvic pain severity ≥4 in the last 7 days;\n4. Pelvic muscle tenderness pain level ≥4.\n\nExclusion Criteria:\n\n1. Previous vaginal or vulvar laser therapy;\n2. Receiving concurrent pelvic physical therapy;\n3. Unable to tolerate vaginal\u002Fpelvic examination\n4. Taking drugs that have heat- or light- sensitive contraindications;\n5. Subjectively reports abnormal or decreased sensation in the vagina or rectum;\n6. History of cancer of the cervix, vagina, uterus, bladder, or vulva or suspected of having neoplasia or pre-cancerous lesions;\n7. History of autoimmune inflammatory conditions such as vulvar lichen sclerosis or other types of dermatoses;\n8. History of vaginal trauma, ulcerations, erosions, or other evidence of vaginal and vulvar skin breakdown;\n9. Less than 6 months post-partum;\n10. Actively trying to get pregnant or not willing to use contraception during the trial;\n11. Positive pregnancy test or planning to get pregnant during the study;\n12. Vaginal discharge or bleeding concerning for neoplasia, infectious, or autoimmune condition; \\*\n13. Pelvic pain has not been fully evaluated or pain is not confirmed as chronic pelvic pain;\n14. Does not speak, read, or writes English and thus cannot complete surveys;\n15. Does not have access to smart digital devices or computer, or cannot receive emails.",{"count":168,"type":19},126,[170],"PHASE2","The goal of this clinical study is to determine if 8 treatments with photobiomodulation using near-infrared laser energy can help reduce chronic pelvic pain in women. Additionally, researchers want to determine if treatment with this type of energy can also alleviate pain with activities such as standing, sitting, urinating, having bowel movements and intercourse.",[88,24],"2024-11-01",{"date":175,"type":39},"2024-11-04",{"date":177,"type":39},"2024-10-17",{"date":179,"type":19},"2026-06",{"name":181,"class":182},"SoLa Pelvic Therapy","INDUSTRY",5]